DDInter387 DDInter1376
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Cisplatin {u} (Compound) treats {v} (Disease) testicular cancer
Cisplatin {u} (Compound) binds {v} (Gene) SLC31A2
Cisplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Cisplatin {u} (Compound) causes {v} (Side Effect) Anaphylactic shock
Cisplatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lithium carbonate
Cisplatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Grepafloxacin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clostridium tetani toxoid antigen (formaldehyde inactivated)
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Cisplatin {u} may lead to a major life threatening interaction when taken with {v} Iothalamic acid
Cisplatin {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Cisplatin (Compound) treats testicular cancer (Disease)
Cisplatin (Compound) binds SLC31A2 (Gene)
Cisplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class)
Cisplatin (Compound) causes Anaphylactic shock (Side Effect)
Cisplatin may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Cisplatin may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Cisplatin may lead to a major life threatening interaction when taken with Iothalamic acid
Cisplatin may lead to a major life threatening interaction when taken with Cladribine